發送短信 : Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

   _____   __   __              ______            
  / ___//  \ \\/ //   ____     /_   _//     ___   
  \___ \\   \ ` //   |    \\    -| ||-     /   || 
  /    //    | ||    | [] ||    _| ||_    | [] || 
 /____//     |_||    |  __//   /_____//    \__ || 
`-----`      `-`'    |_|`-`    `-----`      -|_|| 
                     `-`                     `-`